一次情報の記録
第3相LOTIS-5試験は主要評価項目を達成し、ロンカスツキシマブ テシリン+リツキシマブがR-GemOxに対して統計的に有意なPFS改善を示しました(HR 0.73、p=0.0083)。これにより、この併用療法は2次治療以降のr/r DLBCLにおける新たな標準治療の可能性を確立し、規制当局への申請手続きを後押しします。
ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program News provided by ADC Therapeutics SA Nov 04, 2026, 09:00 ET Share this article Share this article ZYNLONTA data to be featured across 5 oral presentations and multiple posters Phase 1b LOTIS-7 abstract data demonstrates an 88.7% ORR and 75.3% CR with ZYNLONTA plus glofitamab across the 97 efficacy-evaluable r/r DLBCL patients Phase 2 marginal zone lymphoma IIT abstract shows robust and durable 93% ORR and 74.4% CRR with ZYNLONTA monotherapy Company to host conference call today at 4:15 p.m. EST LAUSANNE, Switzerland , Nov. 4, 2026 /PRNewswire/ -- AD
ADC Therapeutics Announces Financial Restructuring and ASH 2026 Data Presentations for ZYNLONTA